Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients

Huysentruyt, Koen;Stephenne, Xavier;Varma, Sharat;Scheers, Isabelle;Sokal, Etienne;et.al.
(2017) Liver Transplantation — Vol. 23, n° 4, p. 552-553 (2017)

Files

document.pdf
  • Restricted Access
  • Adobe PDF
  • 93.72 KB
Request a copy

Details

Authors
Show more
Abstract
(en) The longterm results of pediatric liver transplantation (LT) have become exceptionally good, with >95% longterm survival,1 but hepatitis C virus (HCV) recurrence for a liver graft was an important cause of morbidity, making prevention of disease relapse after transplantation a major objective.2 Treating HCV in children remains challenging,3 but the development of oral direct‐acting antivirals (DAAs) has revolutionized the modern approach for HCV treatment in adults. We describe 2 cases of pediatric HCV patients treated with sofosbuvir (SOF)/ledipasvir (LDV) and ribavirin: one treated before LT (a 1‐year‐old boy transplanted for biliary atresia) and the other after LT (a 16‐year‐old girl transplanted for Budd‐Chiari syndrome and cirrhosis). [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Huysentruyt, K., Stephenne, X., Varma, S., Scheers, I., Leclercq, G., Smets, F., & Sokal, E. (2017). Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients. Liver Transplantation, 23(4), 552-553. https://doi.org/10.1002/lt.24692 (Original work published 2017)